Transurethral resection of the prostate is still the standard treatment of benign BPH but the surgical lasers recently introduced seem to offer the patient a very low perioperative complication rate, a short learning curve, and reduced perating time. A recently introduced high-powered diode laser (980nm) offers a simultaneous absorption in water and hemoglobin but is lacking clinical experience. In this clinical trial study, the feasibility, and postoperative outcome of vaporization of prostate by means of a diode laser were investigated and compared with Transurethral resection of the prostate as a gold standard treatment.
One hundred patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia will include in this study.Patients will assign to two fifty-patient groups according to the method of surgical treatment:Transurethral resection of the prostate and high-powered diode laser (980nm).
All patients underwent physical examination and evaluation of symptoms according to the International Prostate Symptoms Score (IPSS). Blood tests included blood cell count, serum chemistry, serum prostate-specific antigen (PSA), and urine analysis. Additionally, post-void residual urine volume (PVR) and the peak urinary flow rate (Qmax) will measure. Prostate size assesse by transrectal ultra-sound (TRUS). Demographic characteristics, the duration of the operation, the changes in hemoglobin and serum sodium, the complications, the hospitalization period and the duration of indwelling catheter compare between the two aforesaid groups.